The Valley Desk

NCT00144911 · Interventional trial

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Overall registry status Completed

Phase 4

Conditions Pulmonary Disease, Chronic Obstructive

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov